雲南建投混凝土(01847.HK)公開發售超購約18.46倍 預期10月31日上市
格隆匯10月30日丨雲南建投混凝土(01847.HK)公佈,全球發售1.34億股,其中香港發售4016.6萬股,國際發售9371.6萬股;發售價每股3.36港元;每手1,000股;預期10月31日上市。
公告稱,香港公開發售下初步可供認購總數為香港發售股份約18.46倍。國際發售下初步提呈發售的國際發售股份已獲適度超額認購。根據國際發售向承配人分配的發售股份最終數目為9371.6萬股發售股份,佔全球發售下發售股份總數約70%。
基石投資者方面,中聯香港認購1338.8萬股及華潤水泥(香港)認購4016.4萬股。
此外,所得款項淨額估計約為3.64億港元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.